Redhill Biopharma Ltd (RDHL) 14.01 $RDHL
RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application
GlobeNewswire - Mon Apr 07, 7:01AM CDT
-- The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients
RedHill Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 7:06AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference, on Tuesday, March 11, 2014, at 01:00 p.m. PT at the Ritz Carlton, Dana Point, California.
RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.
RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Tue Feb 25, 7:10AM CST
2013 Key Highlights Include:
KEW Group concludes private financing with Cardinal Health and The Bolyston Street Group
M2 - Tue Feb 25, 6:21AM CST
Oncology company KEW Group revealed on Monday the completion of a private round of financing with Cardinal Health (NYSE:CAH) and The Bolyston Street Group.
We're Committed to Improving the Living Standards of Nigerians - Jonathan
by Ben Agande - All Africa Global Media - Fri Feb 14, 3:02AM CST
President Goodluck Jonathan, yesterday, said improvement of the living standards of Nigerians was a commitment his administration was resolutely pursuing.
Left Ventricular Dysfunction - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/45g5zb/left_ventricular) has announced the addition of the "Left Ventricular Dysfunction - Pipeline Review, H2 2013" report to their offering. 'Left Ventricular Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction. Scope - A snapshot of the global therapeutic scenario for Left Ventricular Dysfunction. - A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Left Ventricular Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Left Ventricular Dysfunction Overview Therapeutics Development Pipeline Products for Left Ventricular Dysfunction - Overview Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis Late Stage Products Clinical Stage Products Early Stage Products Assessment by Monotherapy Products Drug Profiles carvedilol CR - Drug Profile carvedilol CR - Drug Profile omecamtiv mecarbil - Drug Profile bromocriptine - Drug Profile CAP-1002 - Drug Profile cimaglermin alfa - Drug Profile CPI-003 - Drug Profile DIOHF - Drug Profile carvedilol CR - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Companies Mentioned Amgen Inc. Acorda Therapeutics, Inc. Innopharmax Inc. RedHill Biopharma Ltd. Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/45...entricular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bioassociate Reiterated BUY Recommendation on RedHill Biopharma Following February 2014 Update
PR Newswire - Mon Feb 10, 7:00AM CST
In a report published on February 9, 2014, Bioassociate reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL) (TASE: RDHL.TA), and set an ADS price target of $18.1. The report contains a detailed discussion of RedHill's pipeline advancements during the preceding months and adjusted cash flows. The Update Report is available at:
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data
RedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; RedHill and IntelGenx plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks, based on available data
RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement
GlobeNewswire - Wed Jan 22, 5:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, announced that it has closed, on January 21, 2014, its previously announced private placement (the "Private Placement" of ordinary shares and warrants for approximately $11.7 million.
RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement
GlobeNewswire - Tue Jan 14, 5:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that it has entered into a definitive agreement with a select group of investors (the "Investors" for the sale of RedHill's ordinary shares and warrants in a private placement transaction (the "Private Placement" for a total amount of approximately $11.7 million.
RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn's Study
GlobeNewswire - Mon Jan 06, 7:01AM CST
-- Preliminary positive safety results received from a Phase I study with RHB-104 in 84 healthy adult subjects
RedHill Biopharma Sells ADS Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 4:50PM CST
RedHill Biopharma recently announced that it has entered into a definitive agreement with Broadfin Capital LLC.
RedHill Biopharma Sells ADS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:09PM CST
RedHill Biopharma recently announced that it entered into a definitive agreement with OrbiMed Israel Partners Limited Partnership the sale of American Depository Shares and warrants in a private placement transaction for $6.0 million.
RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application
GlobeNewswire - Mon Apr 07, 7:01AM CDT
-- The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients
RedHill Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 7:06AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference, on Tuesday, March 11, 2014, at 01:00 p.m. PT at the Ritz Carlton, Dana Point, California. RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
, a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines. RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines. RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Tue Feb 25, 7:10AM CST
2013 Key Highlights Include:
KEW Group concludes private financing with Cardinal Health and The Bolyston Street Group
M2 - Tue Feb 25, 6:21AM CST
Oncology company KEW Group revealed on Monday the completion of a private round of financing with Cardinal Health (NYSE:CAH) and The Bolyston Street Group.
We're Committed to Improving the Living Standards of Nigerians - Jonathan
by Ben Agande - All Africa Global Media - Fri Feb 14, 3:02AM CST
President Goodluck Jonathan, yesterday, said improvement of the living standards of Nigerians was a commitment his administration was resolutely pursuing.
Left Ventricular Dysfunction - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/45g5zb/left_ventricular) has announced the addition of the "Left Ventricular Dysfunction - Pipeline Review, H2 2013" report to their offering. 'Left Ventricular Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction. Scope - A snapshot of the global therapeutic scenario for Left Ventricular Dysfunction. - A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Left Ventricular Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Left Ventricular Dysfunction Overview Therapeutics Development Pipeline Products for Left Ventricular Dysfunction - Overview Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis Late Stage Products Clinical Stage Products Early Stage Products Assessment by Monotherapy Products Drug Profiles carvedilol CR - Drug Profile carvedilol CR - Drug Profile omecamtiv mecarbil - Drug Profile bromocriptine - Drug Profile CAP-1002 - Drug Profile cimaglermin alfa - Drug Profile CPI-003 - Drug Profile DIOHF - Drug Profile carvedilol CR - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Companies Mentioned Amgen Inc. Acorda Therapeutics, Inc. Innopharmax Inc. RedHill Biopharma Ltd. Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/45...entricular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bioassociate Reiterated BUY Recommendation on RedHill Biopharma Following February 2014 Update
PR Newswire - Mon Feb 10, 7:00AM CST
In a report published on February 9, 2014, Bioassociate reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL) (TASE: RDHL.TA), and set an ADS price target of $18.1. The report contains a detailed discussion of RedHill's pipeline advancements during the preceding months and adjusted cash flows. The Update Report is available at:
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data
RedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; RedHill and IntelGenx plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks, based on available data
RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement
GlobeNewswire - Wed Jan 22, 5:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, announced that it has closed, on January 21, 2014, its previously announced private placement (the "Private Placement" of ordinary shares and warrants for approximately $11.7 million. RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement
GlobeNewswire - Tue Jan 14, 5:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that it has entered into a definitive agreement with a select group of investors (the "Investors" for the sale of RedHill's ordinary shares and warrants in a private placement transaction (the "Private Placement" for a total amount of approximately $11.7 million. RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn's Study
GlobeNewswire - Mon Jan 06, 7:01AM CST
-- Preliminary positive safety results received from a Phase I study with RHB-104 in 84 healthy adult subjects
RedHill Biopharma Sells ADS Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 4:50PM CST
RedHill Biopharma recently announced that it has entered into a definitive agreement with Broadfin Capital LLC.
RedHill Biopharma Sells ADS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:09PM CST
RedHill Biopharma recently announced that it entered into a definitive agreement with OrbiMed Israel Partners Limited Partnership the sale of American Depository Shares and warrants in a private placement transaction for $6.0 million.
